Key facts
- OutSee’s last known valuation is $8.2M (Jun 2025).
- It has raised $6.7M; the latest was Seed Round ($3.4M) in Jan 2026.
- Notable investors include Cambridge Enterprise Ventures, University of Bristol, Empirical Ventures, Ahren Innovation Capital, BioIndustry Association — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for OutSee
- ·The full record, as it builds
Funding rounds
No funding rounds for OutSee are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OutSee
Developer of an AI genomics technology designed to analyze genetic data for novel discoveries in drug development and precision medicine. The company's technology enhances standard analysis methods to identify potential causal mechanisms in diseases, approaches to identify disease causes, and informs drug discovery efforts, even with datasets previously analyzed by other methods, enabling researchers to gain additional insights from existing genetic datasets.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2022
- Employees
- 8
- Website
- outsee.co.uk/
- Ownership
- Privately Held (backing)
OutSee doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OutSee shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OutSee in its N-PORT filings yet. We sweep new filings monthly.